A multicenter comparison study between the Endosafe® PTS™ rapid-release testing system and traditional methods for detecting endotoxin in cell-therapy products

A. P. Gee, D. Sumstad, J. Stanson, P. Watson, J. Proctor, Diane M Kadidlo, E. Koch, J. Sprague, D. Wood, D. Styers, David H McKenna, J. Gallelli, D. Griffin, E. J. Read, B. Parish, R. Lindblad

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Rapid-release testing reduces the waiting period for administration of time-sensitive cell-therapy products. Current assay systems are labor intensive and time consuming. The Endosafe® portable test system (PTS™) is a chromogenic Limulus amebocyte lysate (LAL) portable endotoxin detection system that provides quantitative results in approximately 15 min. To evaluate Endosafe® performance with cell-therapy products, side-by-side testing of traditional LAL systems and the Endosafe® system was conducted at the Production Assistance for Cellular Therapies (PACT) facilities and the National Institutes of Health's Department of Transfusion Medicine, USA. Methods: Charles River Laboratories provided each center with a PTS™ reader and two commercially prepared lyophilized reference standard endotoxin (RSE) vials. All samples tested with the Endosafe® system used 0.05-5.0 endotoxin unit/mL (EU/mL) sensitivity cartridges provided by Charles River. Each vial was reconstituted with LAL water and tested in triplicate using the Endosafe® and in-house LAL methods. Subsequently, each center tested the endotoxin content of standard dilutions of cell-therapy products, thus creating paired test results for each sample. Additionally, fabricated endotoxin-positive samples containing varying concentrations of endotoxin were prepared and shipped to all centers to perform blinded testing. Results: Valid paired results, based on each center's LAL method and the Endosafe® system criteria, were analyzed. Endotoxin detection between paired results was equivalent in most cases. Discussion: The Endosafe® system provided reliable results with products typically produced in cell-therapy manufacturing facilities, and would be an appropriate test on which to base the release of time-sensitive cell-therapy products.

Original languageEnglish (US)
Pages (from-to)427-435
Number of pages9
JournalCytotherapy
Volume10
Issue number4
DOIs
StatePublished - Jan 1 2008

Fingerprint

Cell- and Tissue-Based Therapy
Endotoxins
Horseshoe Crabs
Multicenter Studies
Rivers
Transfusion Medicine
National Institutes of Health (U.S.)
endotoxin binding proteins
Water

Keywords

  • Comparability
  • Endosafe® PTS™
  • Endotoxin
  • Limulus amebocyte lysate

Cite this

A multicenter comparison study between the Endosafe® PTS™ rapid-release testing system and traditional methods for detecting endotoxin in cell-therapy products. / Gee, A. P.; Sumstad, D.; Stanson, J.; Watson, P.; Proctor, J.; Kadidlo, Diane M; Koch, E.; Sprague, J.; Wood, D.; Styers, D.; McKenna, David H; Gallelli, J.; Griffin, D.; Read, E. J.; Parish, B.; Lindblad, R.

In: Cytotherapy, Vol. 10, No. 4, 01.01.2008, p. 427-435.

Research output: Contribution to journalArticle

Gee, AP, Sumstad, D, Stanson, J, Watson, P, Proctor, J, Kadidlo, DM, Koch, E, Sprague, J, Wood, D, Styers, D, McKenna, DH, Gallelli, J, Griffin, D, Read, EJ, Parish, B & Lindblad, R 2008, 'A multicenter comparison study between the Endosafe® PTS™ rapid-release testing system and traditional methods for detecting endotoxin in cell-therapy products', Cytotherapy, vol. 10, no. 4, pp. 427-435. https://doi.org/10.1080/14653240802075476
Gee, A. P. ; Sumstad, D. ; Stanson, J. ; Watson, P. ; Proctor, J. ; Kadidlo, Diane M ; Koch, E. ; Sprague, J. ; Wood, D. ; Styers, D. ; McKenna, David H ; Gallelli, J. ; Griffin, D. ; Read, E. J. ; Parish, B. ; Lindblad, R. / A multicenter comparison study between the Endosafe® PTS™ rapid-release testing system and traditional methods for detecting endotoxin in cell-therapy products. In: Cytotherapy. 2008 ; Vol. 10, No. 4. pp. 427-435.
@article{765290ee1c1b4f9ea16e6e5eb208c016,
title = "A multicenter comparison study between the Endosafe{\circledR} PTS™ rapid-release testing system and traditional methods for detecting endotoxin in cell-therapy products",
abstract = "Background: Rapid-release testing reduces the waiting period for administration of time-sensitive cell-therapy products. Current assay systems are labor intensive and time consuming. The Endosafe{\circledR} portable test system (PTS™) is a chromogenic Limulus amebocyte lysate (LAL) portable endotoxin detection system that provides quantitative results in approximately 15 min. To evaluate Endosafe{\circledR} performance with cell-therapy products, side-by-side testing of traditional LAL systems and the Endosafe{\circledR} system was conducted at the Production Assistance for Cellular Therapies (PACT) facilities and the National Institutes of Health's Department of Transfusion Medicine, USA. Methods: Charles River Laboratories provided each center with a PTS™ reader and two commercially prepared lyophilized reference standard endotoxin (RSE) vials. All samples tested with the Endosafe{\circledR} system used 0.05-5.0 endotoxin unit/mL (EU/mL) sensitivity cartridges provided by Charles River. Each vial was reconstituted with LAL water and tested in triplicate using the Endosafe{\circledR} and in-house LAL methods. Subsequently, each center tested the endotoxin content of standard dilutions of cell-therapy products, thus creating paired test results for each sample. Additionally, fabricated endotoxin-positive samples containing varying concentrations of endotoxin were prepared and shipped to all centers to perform blinded testing. Results: Valid paired results, based on each center's LAL method and the Endosafe{\circledR} system criteria, were analyzed. Endotoxin detection between paired results was equivalent in most cases. Discussion: The Endosafe{\circledR} system provided reliable results with products typically produced in cell-therapy manufacturing facilities, and would be an appropriate test on which to base the release of time-sensitive cell-therapy products.",
keywords = "Comparability, Endosafe{\circledR} PTS™, Endotoxin, Limulus amebocyte lysate",
author = "Gee, {A. P.} and D. Sumstad and J. Stanson and P. Watson and J. Proctor and Kadidlo, {Diane M} and E. Koch and J. Sprague and D. Wood and D. Styers and McKenna, {David H} and J. Gallelli and D. Griffin and Read, {E. J.} and B. Parish and R. Lindblad",
year = "2008",
month = "1",
day = "1",
doi = "10.1080/14653240802075476",
language = "English (US)",
volume = "10",
pages = "427--435",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - A multicenter comparison study between the Endosafe® PTS™ rapid-release testing system and traditional methods for detecting endotoxin in cell-therapy products

AU - Gee, A. P.

AU - Sumstad, D.

AU - Stanson, J.

AU - Watson, P.

AU - Proctor, J.

AU - Kadidlo, Diane M

AU - Koch, E.

AU - Sprague, J.

AU - Wood, D.

AU - Styers, D.

AU - McKenna, David H

AU - Gallelli, J.

AU - Griffin, D.

AU - Read, E. J.

AU - Parish, B.

AU - Lindblad, R.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Background: Rapid-release testing reduces the waiting period for administration of time-sensitive cell-therapy products. Current assay systems are labor intensive and time consuming. The Endosafe® portable test system (PTS™) is a chromogenic Limulus amebocyte lysate (LAL) portable endotoxin detection system that provides quantitative results in approximately 15 min. To evaluate Endosafe® performance with cell-therapy products, side-by-side testing of traditional LAL systems and the Endosafe® system was conducted at the Production Assistance for Cellular Therapies (PACT) facilities and the National Institutes of Health's Department of Transfusion Medicine, USA. Methods: Charles River Laboratories provided each center with a PTS™ reader and two commercially prepared lyophilized reference standard endotoxin (RSE) vials. All samples tested with the Endosafe® system used 0.05-5.0 endotoxin unit/mL (EU/mL) sensitivity cartridges provided by Charles River. Each vial was reconstituted with LAL water and tested in triplicate using the Endosafe® and in-house LAL methods. Subsequently, each center tested the endotoxin content of standard dilutions of cell-therapy products, thus creating paired test results for each sample. Additionally, fabricated endotoxin-positive samples containing varying concentrations of endotoxin were prepared and shipped to all centers to perform blinded testing. Results: Valid paired results, based on each center's LAL method and the Endosafe® system criteria, were analyzed. Endotoxin detection between paired results was equivalent in most cases. Discussion: The Endosafe® system provided reliable results with products typically produced in cell-therapy manufacturing facilities, and would be an appropriate test on which to base the release of time-sensitive cell-therapy products.

AB - Background: Rapid-release testing reduces the waiting period for administration of time-sensitive cell-therapy products. Current assay systems are labor intensive and time consuming. The Endosafe® portable test system (PTS™) is a chromogenic Limulus amebocyte lysate (LAL) portable endotoxin detection system that provides quantitative results in approximately 15 min. To evaluate Endosafe® performance with cell-therapy products, side-by-side testing of traditional LAL systems and the Endosafe® system was conducted at the Production Assistance for Cellular Therapies (PACT) facilities and the National Institutes of Health's Department of Transfusion Medicine, USA. Methods: Charles River Laboratories provided each center with a PTS™ reader and two commercially prepared lyophilized reference standard endotoxin (RSE) vials. All samples tested with the Endosafe® system used 0.05-5.0 endotoxin unit/mL (EU/mL) sensitivity cartridges provided by Charles River. Each vial was reconstituted with LAL water and tested in triplicate using the Endosafe® and in-house LAL methods. Subsequently, each center tested the endotoxin content of standard dilutions of cell-therapy products, thus creating paired test results for each sample. Additionally, fabricated endotoxin-positive samples containing varying concentrations of endotoxin were prepared and shipped to all centers to perform blinded testing. Results: Valid paired results, based on each center's LAL method and the Endosafe® system criteria, were analyzed. Endotoxin detection between paired results was equivalent in most cases. Discussion: The Endosafe® system provided reliable results with products typically produced in cell-therapy manufacturing facilities, and would be an appropriate test on which to base the release of time-sensitive cell-therapy products.

KW - Comparability

KW - Endosafe® PTS™

KW - Endotoxin

KW - Limulus amebocyte lysate

UR - http://www.scopus.com/inward/record.url?scp=47249153203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249153203&partnerID=8YFLogxK

U2 - 10.1080/14653240802075476

DO - 10.1080/14653240802075476

M3 - Article

VL - 10

SP - 427

EP - 435

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 4

ER -